By Martin Mou
Wuxi Biologics (Cayman) Inc. said Wednesday that its net profit for 2020 is expected to rise more than 65% on multiple growth drivers.
The company was able to significantly increase its market share of new integrated projects with its leading technology platform, best-in-industry timeline and excellent execution track record, the Chinese biotech firm said.
Higher investment gains and less-than-expected foreign exchange losses also contributed to profit growth, the company said.
Write to Martin Mou at martin.mou@wsj.com
(END) Dow Jones Newswires
01-27-21 0451ET
